Table 2.
Pathways significantly enriched by each module.
| Module | GeneSet | FDR | Nodes |
|---|---|---|---|
| 0 | SRP-dependent cotranslational protein targeting to membrane(R) | <1.667e-04 | RPL17, RPL36A, RPL13, RPL37, RPL39, RPL7, RPS3A, RPL31, RPS23, RPL35A, SEC11C, RPL26, SRPRB, RPS6, RPS7, RPL23, RPS17, RPL22, RPL21, SEC61G, SRP9 |
| 0 | Eukaryotic Translation Termination(R) | <1.667e-04 | RPL17, RPL36A, RPL13, RPL37, RPL39, RPL7, RPS3A, RPL31, RPS23, RPL35A, RPL26, RPS6, RPS7, RPL23, RPS17, RPL22, RPL21 |
| 0 | Ribosome(K) | <1.667e-04 | RPL17, RPL36A, RPL13, RPL37, RPL39, RPL7, RPS3A, RPL31, RPS23, RPL35A, RPL26, RPS6, RPS7, RPL23, RPS17, RPL22, RPL21 |
| 2 | Mitochondrial translation(R) | <1.000e-03 | MRPS35, MRPS17, MRPS26, MRPL1, MRPS33, MRPL50, MRPL3, MRPS23, MRPS30, MRPL24, MRPL12, ICT1, MRPL38, MRPL39, MRPL48 |
| 2 | Ribosome(K) | <5.000e-04 | MRPS17, MRPL1, MRPL3, MRPL24, MRPL12 |
| 3 | ISG15 antiviral mechanism(R) | <1.000e-03 | NUP160, NUP88, NUP205, NUP107, NUP54, KPNA3 |
| 3 | Hexose transport(R) | <5.000e-04 | NUP160, NUP88, NUP205, NUP107, NUP54 |
| 3 | Metabolism of non-coding RNA(R) | <3.333e-04 | NUP160, NUP88, NUP205, NUP107, NUP54 |
| 5 | NoRC negatively regulates rRNA expression(R) | <1.000e-03 | SAP30, HDAC2, DNMT1, BAZ2A |
| 5 | Signaling events mediated by HDAC Class I(N) | <5.000e-04 | SAP30, HDAC2, FKBP3 |
| 5 | Hedgehog signaling events mediated by Gli proteins(N) | 3.83e-02 | SAP30, HDAC2 |
| 6 | Oxidative stress response(P) | <1.000e-03 | DUSP3, MAP3K4, DUSP14, MAPK14, MAPKAPK5, DUSP12 |
| 6 | MAPK signaling pathway(K) | 8.00e-03 | DUSP3, MAP3K4, MAPK14, MAPKAPK5 |
| 6 | p38 MAPK signaling pathway(N) | 2.17e-02 | MAP3K4, MAPK14 |
| 7 | Muscle contraction(R) | <1.000e-03 | SORBS3, TLN1, ACTA2, MYBPC3, ITGB5, TPM2, TPM1, MYL9 |
| 7 | Hypertrophic cardiomyopathy (HCM)(K) | <5.000e-04 | MYBPC3, ITGB5, TPM2, TPM1, ITGA2B |
| 7 | Dilated cardiomyopathy(K) | <3.333e-04 | MYBPC3, ITGB5, TPM2, TPM1, ITGA2B |
| 8 | Processing of Capped Intron-Containing Pre-mRNA(R) | <1.000e-03 | SRSF2, SNRPA1, SRSF7, HNRNPH1, CPSF2, HNRNPA0, HNRNPU |
| 8 | Spliceosome(K) | <5.000e-04 | SRSF2, SNRPA1, SRSF7, HNRNPU |
| 8 | spliceosomal assembly(B) | 1.33e-03 | SRSF2, SNRPA1 |
| 9 | Regulation of nuclear SMAD2/3 signaling(N) | <1.000e-03 | TFE3, SMAD3, TGIF2 |
| 9 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling(N) | 7.00e-03 | CTDSPL, SMAD3 |
| 10 | Mitotic G2-G2/M phases(R) | <1.000e-03 | OFD1, TUBGCP5, CEP78, TUBA4A, CDK5RAP2, TUBB4B |
| 10 | Assembly of the primary cilium(R) | <5.000e-04 | OFD1, CEP78, TUBA4A, CDK5RAP2, TUBB4B |
| 10 | Protein folding(R) | <3.333e-04 | VBP1, TUBA4A, TUBB4B |
| 11 | Protein processing in endoplasmic reticulum(K) | 2.00e-03 | VCP, DNAJC10, ERLEC1 |
| 11 | Hedgehog ligand biogenesis(R) | 2.15e-02 | VCP, ERLEC1 |
| 12 | Signaling by SCF-KIT(R) | 7.00e-03 | FGF9, FES, PIK3R1 |
| 12 | Nongenotropic Androgen signaling(N) | 9.00e-03 | PELP1, PIK3R1 |
| 12 | Osteopontin-mediated events(N) | 7.67e-03 | GSN, PIK3R1 |
FDR – false discovery rate.